—Around the 2000s, vaccinal strategies that aimed to obtain anti-GD3 immunization have been developed mainly in malignant melanoma or other solid tumors.87 The main immunotherapies developed against GD3 were an anti-idiotypic antibody, Bec2 (xenogeneic protein)-keyhole limpet hemocyanin-adjuvant (KLH). The gene discussed is KCNH4; the disease is melanoma.